L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray

Carcinogenesis

Volumn 26, Issue 1, 2005, Pages 17-25

  Kettunen, E ^a   Nicholson, A G ^b   Nagy, B ^a   Wikman, H ^a,c   Seppanen J K ^d   Stjernvall, T ^c   Ollikainen, T ^c   Kinnula, V ^e   Nordling, S ^a   Hollmen J ^d   Anttila, S ^a,c   Knuutila, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^d AALTO UNIVERSITY   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA4 INTEGRIN; CADHERIN; CHEMOKINE; COMPLEMENTARY DNA; GELATINASE B; NERVE CELL ADHESION MOLECULE L1; SEMAPHORIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA MICROARRAY; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC CODE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; NUCLEOTIDE SEQUENCE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY;

CELL ADHESION; CELL LINE; CHEMOKINES, CXC; DNA, COMPLEMENTARY; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN BETA4; MESOTHELIOMA; NEURAL CELL ADHESION MOLECULE L1; PLEURAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 13444266550     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh276     Document Type: Article

References (52)

1. Travis,W., Colby,T., Shimosato,Y., Corrin,B. and Brambilla,E. in association with L.H.Sobin and pathologists from 14 other countries (1999) Histological Typing of Lung and Pleural Tumors. Springer, Berlin.
2. König,J.E., Tolnay,E., Wiethege,T. and Müller,K.M. (1999) Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virch. Arch., 435, 8-12.
3. Carbone,M., Kratzke,R. and Testa,J. (2002) The pathogenesis of mesothelioma. Semin. Oncol., 29, 2-17.
4. Wagner,J.C., Sleggs,C.A. and Marchand,P. (1960) Diffuse pleural mesotheliomas and asbestos exposure in the Northwestern Cape Province. Br. J. Ind. Med., 17, 260-271.
5. Hirvonen,A., Pelin,K., Tammilehto,L., Karjalainen,A., Mattson,K. and Linnainmaa,K. (1995) Inherited GSTM1 and NAT2 as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res., 55, 2981-2983.
6. Hirvonen,A., Saarikoski,S.T., Linnainmaa,K., Koskinen,K., Husgafvel-Pursiainen,K., Mattson,K. and Vainio,H. (1996) Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J. Natl Cancer Inst., 88, 1853-1856.
7. Carbone,M., Pass,H.I., Rizzo,P., Marinetti,M., Di Muzio,M., Mew,D.J., Levine,A.S. and Procopio,A. (1994) Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene, 9, 1781-1790.
8. Testa,J.R., Carbone,M., Hirvonen,A., Khalili,K., Krynska,B., Linnainmaa,K., Pooley,F.D., Rizzo,P., Rusch,V. and Xiao,G.H. (1998) A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res., 58, 4505-4509.
9. Shukla,A., Gulumian,M., Hei,T., Kamp,D., Rahman,Q. and Mossman,B. (2003) Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radical Biol. Med., 34, 1117-1129.
10. Cheng,J.Q., Jhanwar,S.C., Klein,W.M., Bell,D.W., Lee,W.-C., Altomare,D.A., Nobori,T., Olopade,O.I., Buckler,A.J. and Testa,J.R. (1994) p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res., 54, 5547-5551.
11. Bianchi,A.B., Mitsunaga,S.-I., Cheng,J.Q., Klein,W.M., Jhanwar,S.C., Seizinger,B., Kley,N., Klein-Szanto,A.J.P. and Testa,J.R. (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesothelioma. Proc. Natl Acad. Sci. USA, 92, 10854-10858.
12. Sekido,Y., Pass,H.I., Bader,S., Mew,D.J.Y., Christman,M.F., Gazdar,A.F. and Minna,J.D. (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res., 55, 1227-1231.
13. Murthy,S., Shen,T., De Rienzo,A., Lee,W., Ferriola,P., Jhanwar,S., Mossman,B., Filmus,J. and Testa,J. (2000) Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene, 19, 410-416.
14. Linnainmaa,K., Pelin,K., Vanhala,E., Tuomi,T., Piccoli,C., Fitzgerald,D. and Yamasaki,H. (1993) Gap junctional intercellular communication of primary and asbestos-associated malignant human mesothelial cells. Carcinogenesis, 14, 1597-1602.
15. Hand,D., Mannila,H. and Smyth,P. (2001) Principles of Data Mining. The MIT Press, Boston.
16. Wikman,H., Kettunen,E., Seppänen,J., Karjalainen,A., Hollmén,J., Anttila,S. and Knuutila,S. (2002) Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene, 21, 5804-5813.
17. Niini,T., Vettenranta,K., Hollmén,J. et al. (2002) Expression of myeloid-specific genes in childhood acute lymphoblastic leukemia - a cDNA array study. Leukemia, 16, 2213-2221.
18. Armstrong,S., Staunton,J., Silverman,L., Pieters,R., de Boer,M., Minden,M., Sallan,S., Lander,E., Golub,T. and Korsmeyer,S. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genet., 30, 41-47.
19. Kettunen,E., Anttila,S., Seppänen,J. et al. (2004) Differentially expressed genes in nonsmall cell lung cancer - expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet. Cytogenet., 149, 98-106.
20. Hanley,J. and McNeil,B. (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29-36.
21. Swets,J. (1988) Measuring the accuracy of diagnostic systems. Science, 240, 1285-1293.
22. Good,P. (2000) Permutation Tests - A Practical Guide to Resampling Methods for Testing Hypothesis, 2nd Edn. Springer Verlag, New York.
23. Klominek,J., Robert,K., Hjerpe,A., Wickström,B. and Gahrton,G. (1989) Serum-dependent growth patterns of two, newly established human mesothelioma cell lines. Cancer Res., 49, 6118-6122.
24. Singhal,S., Wiewrodt,R., Malden,L.D. et al. (2003) Gene expression profiling of malignant mesothelioma. Clin. Cancer Res., 9, 3080-3097.
25. Angiolillo,A., Sgadari,C., Taub,D., Liao,F., Farber,J., Maheshwari,S., Kleinman,H., Reaman,G. and Tosato,G. (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 182, 155-162.
26. Zhang,R., Zhang,H., Zhu,W., Pardee,A., Coffey,R.J. and Liang,P. (1997) Mob-1, a Ras target gene, is overexpressed in colorectal cancer. Oncogene, 14, 1607-1610.
27. Soejima,K. and Rollins,B. (2001) A functional IFN-γ-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. J. Immunol., 167, 6576-6582.
28. Visser,C., Tekstra,J., Brouwer-Steenbergen,J., Tuk,C., Boorsma,D., Sampat-Sardjoepersad,S., Meijer,S., Krediet,R. and Beelen,R. (1998) Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES. Clin. Exp. Immunol., 112, 270-275.
29. Mrstik,M., Kotseos,K., Ma,C. and Chegini,N. (2003) Increased expression of interferon-inducible protein-10 during surgically induced peritoneal injury. Wound Repair Regen., 11, 120-126.
30. Koukoulis,G., Shen,J., Monson,R., Warren,W., Virtanen,I. and Gould,V. (1997) Pleural mesotheliomas have an integrin profile distinct from visceral carcinomas. Hum. Pathol., 28, 84-90.
31. Giuffrida,A., Vianale,G., Di Muzio,M., Pass,H., Coletti,A., Birarelli,P., Procopio,A. and Modesti,A. (1999) Modulation of integrin expression on mesotheliomas: the role of different histotypes in invasiveness. Int. J. Oncol., 15, 437-442.
32. Barth,T., Brüderlein,S., Rinaldi,N., Mechtersheimer,G. and Möller,P. (1997) Pleural mesothelioma mimics the integrin profile of activated, sessile rather than detached mesothelial cells. Int. J. Cancer, 72, 77-86.
33. Trusolino,L., Bertotti,A. and Comoglio,P. (2001) A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell, 107, 643-654.
34. Gordon,G.J., Jensen,R.V., Hsiao,L.-L., Gullans,S.R., Blumenstock,J.E., Richards,W.G., Jaklitsch,M.T., Sugarbaker,D.J. and Bueno,R. (2003) Using gene expression ratios to predict outcome among patients with mesothelioma. JNCI Cancer Spectrum, 95, 598-605.
35. Yamada,T., Endo,R., Gotoh,M. and Hirohashi,S. (1997) Identification of semaphorin E as a non-MDR drug resistance gene of human cancers. Proc. Natl Acad. Sci. USA, 94, 14713-14718.
36. Simsir,A., Fetsch,P., Mehta,D., Zakowski,M. and Abati,A. (1999) E-cadherin, N-cadherin and calretinin in pleural effusions: the good, the bad, the worthless. Diagn. Cytopathol., 20, 125-130.
37. Laskin,W. and Miettinen,M. (2002) Epithelial-type and neural-type cadherin expression in malignant noncarcirromatous neoplasms with epithelioid features that involve the soft tissues. Arch. Pathol. Lab. Med., 126, 425-431.
38. Thirkettle,I., Harvey,P., Hasleton,P., Ball,R. and Warn,R. (2000) Immunoreactivity for cadherins, HGF/SF, met and erbB-2 in pleural malignant mesotheliomas. Histopathology, 36, 522-528.
39. Chen,G., Tai,C., Yeh,L., Yang,T. and Tsai,H. (2002) Identification of the cadherin subtypes present in the human peritoneum and endometriotic lesions: potential role for P-cadherin in the development of endometriosis. Mol. Reprod. Dev., 62, 289-294.
40. Patel,I., Madan,P., Getsios,S., Bertrand,M. and MacCalman,C. (2003) Cadherin switching in ovarian cancer progression. Int. J. Cancer, 106, 172-177.
41. Uematsu,K., Kanazawa,S., You,L., He,B., Xu,Z., Li,K., Peterlin,B.M., McCormick,F. and Jablons,D.M. (2003) Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of β-catenin. Cancer Res., 63, 4547-4551.
42. Steinberg,M. and McNutt,P. (1999) Cadherins and their connections: adhesion junctions have broader functions. Curr. Opin. Cell Biol., 11, 554-560.
43. Primiano,T., Baig,M., Maliyekkel,A., Chang,B., Fellars,S., Sadhu,J., Axenovich,S., Holzmayer,T. and Roninson,I. (2003) Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell, 4 41-53.
44. Egeblad,M. and Werb,Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer, 2 161-174.
45. Liu,Z., Ivanoff,A. and Klominek,J. (2001) Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int. J. Cancer, 91, 638-643.
46. Hirano,H., Tsuji,M., Kizaki,T., Sashikata,T., Yoshi,Y., Okada,Y. and Mori,H. (2002) Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study. Med. Electron Microsc., 35, 16-23.
47. Edwards,J., McLaren,J., Jones,J., Waller,D. and O'Byrne,K. (2003) Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br. J. Cancer, 88 1553-1559.
48. Özdemir,O., Emri,S., Karakoca,Y., Sayinalp,N., Akay,H., Dündar,S. and Baris,Í. (1996) Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma. Thrombosis Res., 84, 121-128.
49. Kettunen,E., Nissén,A.M., Ollikainen,T., Taavitsainen,M., Tapper,J., Mattson,K., Linnainmaa,K., Knuutila,S. and El-Rifai,W. (2001) Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int. J. Cancer, 91, 492-496.
50. Mohr,S., Keith,G., Galateau-Salle,F., Icard,P. and Rihn,B. (2004) Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. Biochim. Biophys. Acta 1688, 43-60.
51. Gordon,G., Jensen,R., Hsiao,L., Gullans,S., Blumenstock,J., Ramaswamy,S., Richards,W., Sugarbaker,D. and Bueno,R. (2002) Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 62, 4963-4967.
52. Pass,H.I., Liu,Z., Wali,A., Bueno,R., Land,S., Lott,D., Siddiq,F., Lonardo,F., Carbone,M. and Draghici,S. (2004) Gene expression profiles predict survival and progression of pleural mesothelioma. Clin. Cancer Res., 10, 849-859.